Study of BBT002 for COPD and Nasal Polyps
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests a new drug, BBT002, first in healthy volunteers and then in people with chronic obstructive pulmonary disease (COPD) or chronic sinusitis with nasal polyps. It aims to see if the drug is safe and how it works in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a healthy volunteer aged 18–65, or a person with COPD aged 35–80, or a person with nasal polyps aged 18–80.
- Your body mass index (BMI) must be between 18 and 32 for healthy volunteers, or between 16 and 35 for patients, and your weight must be under 120 kg (healthy) or 125 kg (patients).
- You must not smoke more than 5 cigarettes a day, or be a non-smoker or ex-smoker.
- You must avoid alcohol for 24 hours before each study visit and use effective contraception if you or your partner could become pregnant.
- You must not have serious health issues like HIV, hepatitis, cancer, autoimmune diseases, or significant heart, lung, liver, or kidney problems.
- If you have COPD, your lung function test must show a specific ratio below 0.70 after using a bronchodilator.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral tablet called RSS0343 for people with moderate to severe COPD. It aims to see if the tablet can improve lung function and reduce flare-ups when added to your current breathing treatments.
This trial tests an experimental drug called BBT002 in healthy volunteers and people with chronic obstructive pulmonary disease (COPD), a lung condition that makes breathing hard. It aims to see if the drug is safe and how the body processes it.
This study tests a new drug called BBT002 in healthy people and in patients with chronic sinusitis and nasal polyps, with or without asthma. It aims to see if the drug is safe and effective for reducing symptoms.
This study tests a new medication (GSK5784283) for people with moderate to severe COPD who have a certain type of inflammation (eosinophilic). Participants must be on standard inhaler therapy and have a history of smoking. The trial will compare the new drug to a placebo.
This trial tests a new inhaled drug, HSK39004, to see if it safely improves breathing and quality of life in people with moderate to severe COPD. You may join if you are between 40 and 80, have a COPD diagnosis with certain lung function results, and have at least some shortness of breath with daily activities.
This is an early-stage study testing a new inhaled medication (HRS-9821) to see if it is safe and how the body processes it. Researchers will first test it in healthy volunteers, then in people with COPD (chronic lung disease) to understand if it might help with breathing.
Hear when a new Chronic Obstructive Pulmonary Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.